Befejeződött2. fázis
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Key facts
- Where
- Budapest, Budapest II és Veszprem, MagyarországSee the 3 sites
- Phase
- 2. fázis
Where in Magyarország
- Qualiclinic Kft.Budapest, MagyarországNo longer taking part
- Revita Kft.Budapest II, MagyarországNo longer taking part
- Vital-Medicina Kft.Veszprem, MagyarországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly & Co.
- Trial code
- EU 2022-501425-20-00
- Record updated
- 2024. május 14.
- Original description
To evaluate the efficacy of peresolimab compared to placebo in achieving ACR20Read full original descriptionShow less
J1A-MC-KDAF: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis
To evaluate the efficacy of peresolimab compared to placebo in achieving ACR20
Inclusion: Have a diagnosis of adult onset rheumatoid arthritis for at least 3 months.
Exclusion: Had cancer within the last 5 years, except for some types of skin cancer or cervical cancer; Had certain types of infections within the last 3 months; Have HIV; Have current hepatitis virus B or C infection; Had cervical dysplasia.